Utilizing Telemedicine to Engage Rural Patients With Substance Use Disorders in Low Barrier Hepatitis C Treatment
Kristi Hill(Johns Hopkins University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Sherilyn Brinkley, Maria C. Latimer, David L. Thomas(Johns Hopkins University), Jackie Bittner(Johns Hopkins University), Mark S. Sulkowski(Johns Hopkins University), Patricia Tichnell(Johns Hopkins University), Tracy Agee(Johns Hopkins University)
Cited by 1
Related Papers
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
|Mycoses|2011|159
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
|UNC Libraries|2020|111
Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era
|Journal of Viral Hepatitis|2018|104